Study S001292

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02773381
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 15
Start: 2016-06-02
Primary completion: 2018-10-19
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:semaglutide; DRUG:placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2015-003998-14; OTHER:U1111-1174-1070; NIH:2015

Registered primary outcomes

Area under the serum glucose concentration-time curve [At 12 weeks of treatment]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023631	Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Gibbons C, Diabetes, obesity & metabolism	2021	Randomized trial	PMID 33184979 DOI	cites ClinicalTrials.gov:NCT02773381; registry reference RESULT:33184979